SID 2026Abstract 0465
Roflumilast foam 0.3% in patients with seborrheic dermatitis and prior inadequate response, intolerance, and/or contraindications to topical antifungals and/or topical corticosteroids
Chovatiya R, Domingues E, Lain E, Hong H, Schlesinger T, Woolery-Lloyd H, Krupa D, Jaworski JC, Seal MS, Hanna D, Burnett P, Stephenson B
SID Annual Meeting 2026Chicago, 13–16 May 2026 · published in JID 21 Jul 2026
Topics: Atopic dermatitis & eczemaInfections & infestations
Abstract
The abstract’s text is on the JID website.
DOI 10.1016/j.jid.2026.06.496 · Not in PubMed: details from Crossref